Trial Profile
Phase II study of arsenic trioxide in patients with multiple myeloma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2020
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Therapeutic Use
- Sponsors CTI BioPharma
- 02 Oct 2020 Status changed from active, no longer recruiting to discontinued.
- 30 Sep 2005 New trial record.